Jian Lun Xu

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer
    Jian Lun Xu
    Biometry Research Group, National Cancer Institute, Bethesda, MD, USA
    Gynecol Oncol 125:70-4. 2012
  2. ncbi Estimating the cumulative risk of a false-positive test in a repeated screening program
    Jian Lun Xu
    Biometry Research Group, National Cancer Institute, Bethesda, Maryland 20892 7354, USA
    Biometrics 60:651-60. 2004
  3. ncbi Modelling and analysing exchangeable binary data with random cluster sizes
    Jian Lun Xu
    Biometry Research Group, National Cancer Institute, Executive Plaza North, Suite 3131, 6130 Executive Blvd, MSC 7354, Bethesda, MD 20892 7354, USA
    Stat Med 22:2401-16. 2003
  4. ncbi Cumulative incidence of false-positive results in repeated, multimodal cancer screening
    Jennifer Miller Croswell
    Office of the Director, Office of Disease Prevention, National Institutes of Health, 6100 Executive Blvd, Suite 2B 03, Bethesda, MD 20892, USA
    Ann Fam Med 7:212-22. 2009
  5. ncbi The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial
    Christine C Johnson
    Josephine Ford Cancer Center, Henry Ford Hospital, Detroit, MI, USA
    Gynecol Oncol 110:383-9. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer
    Jian Lun Xu
    Biometry Research Group, National Cancer Institute, Bethesda, MD, USA
    Gynecol Oncol 125:70-4. 2012
    ..To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer...
  2. ncbi Estimating the cumulative risk of a false-positive test in a repeated screening program
    Jian Lun Xu
    Biometry Research Group, National Cancer Institute, Bethesda, Maryland 20892 7354, USA
    Biometrics 60:651-60. 2004
    ..The extension of the new model by incorporating covariate information is also considered. We apply our testing method and the new model to data from the breast cancer screening trial of the Health Insurance Plan of Greater New York...
  3. ncbi Modelling and analysing exchangeable binary data with random cluster sizes
    Jian Lun Xu
    Biometry Research Group, National Cancer Institute, Executive Plaza North, Suite 3131, 6130 Executive Blvd, MSC 7354, Bethesda, MD 20892 7354, USA
    Stat Med 22:2401-16. 2003
    ..To see the performance of the MLEs with small or moderate sample sizes, several simulation studies are also conducted...
  4. ncbi Cumulative incidence of false-positive results in repeated, multimodal cancer screening
    Jennifer Miller Croswell
    Office of the Director, Office of Disease Prevention, National Institutes of Health, 6100 Executive Blvd, Suite 2B 03, Bethesda, MD 20892, USA
    Ann Fam Med 7:212-22. 2009
    ..We sought to determine the cumulative risk of a false-positive screening result and the resulting risk of a diagnostic procedure for an individual participating in a multimodal cancer screening program...
  5. ncbi The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial
    Christine C Johnson
    Josephine Ford Cancer Center, Henry Ford Hospital, Detroit, MI, USA
    Gynecol Oncol 110:383-9. 2008
    ..To determine the epidemiology of CA-125 in women without ovarian cancer...